XML 43 R27.htm IDEA: XBRL DOCUMENT v3.25.4
Supplemental information
 12 Months Ended
Dec. 31, 2025
Restructuring and Related Activities [Abstract]  
Supplemental information Supplemental information
The Company operates as one reporting segment. The following table presents long-lived assets by location:
December 31,
 20252024
United States$65,669 $62,897 
Israel14,059 16,120 
Switzerland48,125 27,014 
Others19,146 13,560 
Total long-lived assets $146,999 $119,591 
Restructuring
In November 2023, the Company announced a series of actions to strengthen and optimize its business operations to support near-term growth drivers and long-term value creation. The plan included a reduction in headcount of approximately 200 employees or 13% of the Company's then current workforce. The Company incurred restructuring costs (including severance pay, garden leave payments, etc.) for the years ended December 31, 2025, 2024 and 2023, as follows:
Year ended December 31,
 202520242023
Cost of revenues$— $52 $262 
Research, development and clinical studies— 275 2,070 
Sales and marketing— 1,512 2,404 
General and administrative— 164 1,495 
Total restructuring cost
$— $2,003 $6,231 
Restructuring costs paid during the period
$— $5,455 $2,753 
These restructuring costs were offset by accrual reversals for the years ended December 31, 2025, 2024 and 2023 in the amount of $0, $369 and $3,041, respectively, which relate to the terminated employees' exits from the Company’s cash incentive plans. These restructuring costs were further offset by forfeited equity-based compensation expense reversals for the years ended December 31, 2025, 2024 and 2023 in the amount of $0, $1,991 and $9,313, respectively, which relate to the terminated employees' exits from the Company’s equity incentive plan.